Skip to main content
Premium Trial:

Request an Annual Quote

Celltrion Evaluating Crucell's Antibody, Protein Technology

NEW YORK (GenomeWeb News) – Celltrion will evaluate Crucell’s cell lines for use in its drug development services programs under a new licensing agreement, Crucell said today.
 
The non-exclusive agreement allows Celltrion to evaluate Crucell’s STAR technology, which is used in producing recombinant human antibodies and proteins, for its drug programs, Crucell said.
 
Crucell’s STAR technology contains genetic elements that enable stable gene expression that is used in making recombinant antibodies and proteins in mammalian cells. The Leiden, Netherlands-based firm said the technology can help increase the yields and lower the costs of antibody and protein production.
 
Celltrion offers services including cell line development and banking, process development, as well as technical, quality, and regulatory support services.
 
Financial terms of the agreement were not released.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.